SELENBP1 was reduced in breast cancer tissues compared to normal controls; hence, the expression level of SELENBP1 can be used as an essential indicator to predict the efficacy of Se supplementation and survival in breast cancer patients [107]. Here, SELENBP1 is linked to breast carcinoma.